Early chemotherapy de-escalation strategy in patients with advanced-stage Hodgkin lymphoma with negative positron emission tomography scan after 2 escalated BEACOPP cycles.

Abstract

INTRODUCTION Escalated BEACOPP (escBEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) significantly improves overall response rates (ORRs) and prolongs progression‑free survival (PFS) in patients with advanced‑stage Hodgkin lymphoma (HL). However, 6 to 8 cycles of escBEACOPP are associated with increased acute toxicity and late complications. OBJECTIVES We aimed to determine the role of early positron emission tomography-computed tomography (PET‑CT) response assessment in a de‑escalation strategy. PATIENTS AND METHODS We retrospectively analyzed 188 consecutive patients with advanced‑stage HL treated at diagnosis. Patients received 2 cycles of escBEACOPP followed by an early PET‑CT response assessment performed after 2 cycles of chemotherapy (PET2). Patients with an active disease continued therapy with escBEACOPP, while those with negative PET2 were de‑escalated to ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). Radiotherapy was allowed in patients with stage IIBX. RESULTS PET2 allowed for de‑escalation of therapy in 141 patients (75%). Their ORR was 92.2%, with a complete remission (CR) rate of 91.5%; 10‑year PFS and overall survival (OS) were 87.2% and 95%, respectively. In the whole cohort, ORR was 87.8% (CR, 85.6%), while the 10‑year PFS and OS were 79.3% and 89.4%, respectively. Hematological and thromboembolic complications were significantly more frequent in patients treated with 6 escBEACOPP cycles, including febrile neutropenia (25 patients, [53.2%] vs 7 [5%]), serious anemia (35 [74.5%] vs 11 [7.8%]), or thrombocytopenia (16 [34%] vs 7 [5%]) (P <0.001 for all comparisons with de‑escalation strategy) as well as pulmonary embolism (3 [6.4%] vs 0) (P = 0.02). CONCLUSIONS The early de‑escalation strategy allows for effective treatment of advanced HL, with a comparable efficacy to that of 6 to 8 cycles of escBEACOPP, but with significantly reduced toxicity.

• Authors: Monika Długosz-Danecka, Sebastian Szmit, Anna Kocurek, Paweł Koźlik, Agnieszka Giza, Dagmara Zimowska-Curyło, Bogdan Małkowski, Anna Sowa-Staszczak, Jarosław Kużdżał, Wojciech Jurczak
• Journal: Polish archives of internal medicine (Pol Arch Intern Med) Vol. 129 Issue 4 Pg. 259-266 (04 30 2019) ISSN: 1897-9483 [Electronic] Poland
• PMID: 30945698 (Publication Type: Journal Article)

Chemical References

• Bleomycin
• Procarbazine
• Vincristine
• Etoposide
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bleomycin (adverse effects, therapeutic use)
• Cyclophosphamide (adverse effects, therapeutic use)
• Dose-Response Relationship, Drug
• Doxorubicin (adverse effects, therapeutic use)
• Etoposide (adverse effects, therapeutic use)
• Female
• Follow-Up Studies
• Hodgkin Disease (diagnostic imaging, drug therapy, physiopathology)
• Humans
• Male
• Middle Aged
• Positron Emission Tomography Computed Tomography
• Prednisone (adverse effects, therapeutic use)
• Procarbazine (adverse effects, therapeutic use)
• Retrospective Studies
• Survival Analysis
• Treatment Outcome
• Vincristine (adverse effects, therapeutic use)